Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
January 31 2023 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections, today announced that it plans to report its
financial results for its fiscal first quarter ended December 31,
2022 after the U.S. market closes on February 7, 2023. Enanta
management will host a conference call at 4:30 p.m. ET to discuss
these results and provide an update on Enanta’s business, including
its research and development pipeline.
Conference Call and Webcast Information
The live webcast can be accessed under "Events &
Presentations" in the investors section of Enanta’s website. To
participate by phone, please register for the call here. It is
recommended that participants register a day in advance or at a
minimum of 15 minutes before the call. Once registered,
participants will receive an email with the dial-in information.
The archived webcast will be available on Enanta’s website for
approximately 30 days following the event.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections. Enanta’s research and development programs include
clinical candidates for the following disease targets: respiratory
syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus
(HBV). Enanta is also conducting research in human metapneumovirus
(hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is part of one of the leading treatment
regimens for curing chronic HCV infection and is sold by AbbVie in
numerous countries under the tradenames MAVYRET® (U.S.) and
MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit
www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230131005112/en/
Media and Investor Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024
